<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Clin Rheumatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Clin. Rheumatol</journal-id>
      <journal-title-group>
        <journal-title>Clinical Rheumatology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0770-3198</issn>
      <issn pub-type="epub">1434-9949</issn>
      <publisher>
        <publisher-name>Springer London</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24221504</article-id>
      <article-id pub-id-type="pmc">4000421</article-id>
      <article-id pub-id-type="publisher-id">2423</article-id>
      <article-id pub-id-type="doi">10.1007/s10067-013-2423-z</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Based Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Attenuated osteoarticular phenotype of type VI mucopolysaccharidosis: a report of four patients and a review of the literature</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Jurecka</surname>
            <given-names>Agnieszka</given-names>
          </name>
          <address>
            <email>ajurecka@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff6"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zakharova</surname>
            <given-names>Ekaterina</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Malinova</surname>
            <given-names>Vera</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3"/>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Voskoboeva</surname>
            <given-names>Elena</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tylki-Szyma&#x144;ska</surname>
            <given-names>Anna</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5"/>
        </contrib>
        <aff id="Aff1"><label/>Department of Medical Genetics, The Children&#x2019;s Memorial Health Institute, Al. Dzieci Polskich 20, 04-730 Warsaw, Poland </aff>
        <aff id="Aff2"><label/>Department of Inherited Metabolic Diseases, Research Center for Medical Genetics, Moscow, Russia </aff>
        <aff id="Aff3"><label/>Department of Pediatrics and Adolescence Medicine, General University Hospital, Prague, Czech Republic </aff>
        <aff id="Aff4"><label/>First Faculty of Medicine, Charles University, Prague, Czech Republic </aff>
        <aff id="Aff5"><label/>Department of Pediatrics, Nutrition and Metabolic Diseases, The Children&#x2019;s Memorial Health Institute, Warsaw, Poland </aff>
        <aff id="Aff6"><label/>Department of Genetics, University of Gdansk, Gdansk, Poland </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>13</day>
        <month>11</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>13</day>
        <month>11</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2014</year>
      </pub-date>
      <volume>33</volume>
      <issue>5</issue>
      <fpage>725</fpage>
      <lpage>731</lpage>
      <history>
        <date date-type="received">
          <day>26</day>
          <month>9</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>18</day>
          <month>10</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2013</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p>Mucopolysaccharidosis type VI (Maroteaux&#x2013;Lamy syndrome, MPS VI, OMIM 253200) is caused by mutations in the gene coding for <italic>N</italic>-acetylgalactosamine-4-sulfatase (4-sulfatase, arylsulfatase B, ARSB, EC 3.1.6.12), a lysosomal enzyme involved in the degradation of dermatan sulfate (DS). The clinical presentation of MPS VI varies greatly with respect to age of onset and rate of disease progression. This report focuses on the attenuated form of MPS VI, which can go unrecognized for years and often presents with atypical signs or symptoms. We described a cohort of MPS VI patients (<italic>n</italic>&#x2009;=&#x2009;4) heterozygous for the p.Y210C mutation who had a significant osteoarticular involvement at the onset of their disease and who were diagnosed years or even decades later. We have also reviewed the literature (<italic>n</italic>&#x2009;=&#x2009;36). Two types of attenuated MPS VI phenotypes could be distinguished: osteoarticular and cardiac. The majority of MPS VI patients reported so far as relatively attenuated presented with an essentially osteoarticular phenotype associated with the p.Y210C mutation. Patients homozygous for the p.R152W mutation presented with a cardiac phenotype, which, despite fulfilling the generally used criteria for attenuated phenotype, may lead to fast disease progression and abrupt death. The knowledge of natural history and genotype&#x2013;phenotype correlation may help in developing a tailored therapy potentially using enzyme replacement therapy with substrate reduction therapy or chaperones.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Attenuated phenotype</kwd>
        <kwd>Cardiac phenotype</kwd>
        <kwd>Genotype&#x2013;phenotype analysis</kwd>
        <kwd>Maroteaux&#x2013;Lamy syndrome</kwd>
        <kwd>Mucopolysaccharidosis type VI</kwd>
        <kwd>Osteoarticular phenotype</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Clinical Rheumatology 2014</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>Mucopolysaccharidosis type VI (Maroteaux&#x2013;Lamy syndrome, MPS VI, OMIM 253200) is an inherited metabolic disease caused by a deficient activity of <italic>N</italic>-acetylgalactosamine-4-sulfatase (4-sulfatase, arylsulfatase B, ARSB, EC 3.1.6.12), a lysosomal enzyme involved in the degradation of dermatan sulfate (DS) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. The clinical presentation of MPS VI varies greatly with respect to age of onset and rate of disease progression. Descriptive classification systems have described patients&#x2019; phenotypes as severe (with early onset of symptoms and fast progression), attenuated (with later onset, slower disease progression, and variable clinical presentation), and intermediate [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Especially in attenuated phenotypes, a definite diagnosis may be delayed for years because early symptoms are difficult to recognize for physicians not familiar with the disease, since the disease progresses silently over decades.</p>
      <p>The incidence rates for this rare disease vary in the literature between 0.05 [<xref ref-type="bibr" rid="CR4">4</xref>] and 2.3 [<xref ref-type="bibr" rid="CR5">5</xref>] diagnosed MPS VI patients per 100,000 live births. Allele frequencies of the different mutations are very low, and most mutations are unique to individual families, except for a high prevalence of p.R152W mutation in Eastern European population [<xref ref-type="bibr" rid="CR6">6</xref>].</p>
      <p>This report focuses on the less severe form of MPS VI. The objective of this article is to show the existence of significant differences between so-called attenuated patients and to highlight the need of close cooperation of different specialties in order to recognize the disease early. The knowledge of natural history and genotype&#x2013;phenotype correlation may also help in developing a tailored therapy.</p>
    </sec>
    <sec id="Sec2" sec-type="materials|methods">
      <title>Patients and methods</title>
      <sec id="Sec3">
        <title>Patient enrollment and data collection</title>
        <p>The lists of diagnosed MPS VI patients were provided by seven diagnostic centers for MPS VI in Central and Eastern Europe (Warsaw, Prague, Vilnius, Minsk, Riga), Russia (Moscow), and Kazakhstan (Almaty). Out of these patients, only patients with the less severe form of MPS VI were included in our study.</p>
        <p>All patients were na&#xEF;ve to enzyme replacement therapy (ERT) at the time of the study.</p>
      </sec>
      <sec id="Sec4">
        <title>Ethical consideration</title>
        <p>The protocol was approved by the Human Subjects Institutional Review Board at the Children&#x2019;s Memorial Health Institute. Written informed consent had to be provided by the parents or legal guardians. All patients and/or their families provided written consents about using their photos.</p>
      </sec>
    </sec>
    <sec id="Sec5" sec-type="results">
      <title>Results</title>
      <sec id="Sec6">
        <title>Patient population</title>
        <p>The main demographic and clinical characteristics of all patients in our series are shown in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>. All of the patients were Caucasian, and no sex predominance was seen. No consanguinity between parents was recorded.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Clinical, biochemical, and molecular data of MPS VI patients heterozygous for p.Y210C mutation</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Case number (country, current age)</th><th>Age at onset of symptoms/age at diagnosis (years)</th><th>Symptoms at onset</th><th>Other symptoms before MPS VI diagnosis</th><th>Misdiagnosis/initial diagnosis</th><th>Extraskeletal involvement during the disease course</th><th>ARSB activity<sup>a</sup>
</th><th>Genotype<sup>b</sup>
</th></tr></thead><tbody><tr><td>1 (Czech Republic, 47)</td><td char="/" align="char">10/45</td><td>DW, HP, JS, RR</td><td>CFF, GR, SK</td><td>Hip dysplasia, Perthes disease</td><td>CH, IH, M, SCC, UH, HC</td><td char="." align="char">10.8</td><td>p.R160X/p.Y210C</td></tr><tr><td>2 (Russia, 40)</td><td char="/" align="char">8/38</td><td>JS</td><td>DW, HP, HC, SCC</td><td>Chondrodysplasia, osteochondrosis</td><td>CFF, HC, SCC</td><td char="." align="char">7.4</td><td>p.Y210C/p.C521Y</td></tr><tr><td>3 (Belarus, 36)</td><td char="/" align="char">8/9</td><td>JS</td><td>No</td><td>Hip dysplasia</td><td>CFF, DW, HP, CFF, RR</td><td char="." align="char">9.8</td><td>p.T92K/p.Y210C</td></tr><tr><td>4 (Russia, 20)</td><td char="/" align="char">5/10</td><td>JS, RR, IH</td><td>No</td><td>No</td><td>CFF, HC</td><td char="." align="char">9.8</td><td>p.N262Kfs*14/p.Y210C</td></tr></tbody></table><table-wrap-foot><p>
<italic>DW</italic> difficulty in walking, <italic>CFF</italic> coarse facial features, <italic>CH</italic> claw hands, <italic>GR</italic> growth retardation, <italic>HC</italic> hydrocephalus, <italic>HP</italic> hip pain, <italic>IH</italic> impaired hearing, <italic>JS</italic> joint stiffness, <italic>M</italic> myelopathy, <italic>RR</italic> recurrent rhinitis, <italic>SCC</italic> spinal cord compression, <italic>SK</italic> skeletal abnormalities, <italic>UH</italic> umbilical hernia</p><p>
<sup>a</sup>ARSB activity in the patients&#x2019; leukocytes was referred to the mean value of several controls analyzed in the same experiment</p><p>
<sup>b</sup>NCBI reference sequence: NM_000046.3 (cDNA considering A of the ATG translation initiation codon as nucleotide +1); NP_000037</p></table-wrap-foot></table-wrap></p>
        <sec id="Sec7">
          <title>First clinical features and disease progression</title>
          <p>For all four patients, the age of first symptom onset ranged from 5 to 8&#xA0;years (median 8&#xA0;years). The most common first sign to appear was decreased joint range of motion of large joints of the upper and/or lower limbs. The most commonly affected joints were hips, which resulted in hip pain with difficulty in walking and stair climbing. The first misdiagnoses in these patients were Perthes disease, hip dysplasia or osteochondrosis. In addition to the joint problems, some of the patient cohort reported features such as recurrent rhinitis, impaired hearing, hydrocephalus, and in the case of older patients, spinal cord compression.</p>
          <p>Within the disease course, the patients developed other disease manifestations such as skeletal abnormalities (Figs.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref> and <xref rid="Fig2" ref-type="fig">2</xref>), growth retardation, and spinal cord compression.<fig id="Fig1"><label>Fig. 1</label><caption><p>
<bold>a</bold>, <bold>b</bold> Radiographs of a patient heterozygous for the p.Y210C mutation. Lateral radiographs of cervical spine: (1) reduction of cervical lordosis, (2) narrowing of L3 vertebral body and dislocation of L4 vertebral body (<italic>arrows</italic>), and (3) thickening of the skull bones</p></caption><graphic xlink:href="10067_2013_2423_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig. 2</label><caption><p>Pictures of MPS VI patients heterozygous for the p.Y210C mutation</p></caption><graphic xlink:href="10067_2013_2423_Fig2_HTML" id="MO2"/></fig></p>
          <p>Joint stiffness was reported in all patients. It was located mainly in the shoulder and hip joints or other large joints of the upper and/or lower limbs. It was intense and significantly impaired the quality of the patient&#x2019;s life leading to consultations by orthopedic surgeons. Typical for MPS contractures of fingers (so-called claw hands) were also observed decreasing the function, efficiency, and skills of the hands.</p>
          <p>At the time of the study, the eldest patients were 45 and 40&#xA0;years of age.</p>
        </sec>
        <sec id="Sec8">
          <title>Delayed diagnosis</title>
          <p>Following the onset of signs and symptoms, MPS VI diagnosis occurred after 9&#xA0;years of age (range 9&#x2013;45&#xA0;years, median 24&#xA0;years) with median delays 17.5&#xA0;years.</p>
        </sec>
      </sec>
      <sec id="Sec9">
        <title>Literature review</title>
        <sec id="Sec10">
          <title>Clinical phenotypes</title>
          <p>The results of the literature review are presented in Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>, which includes only reports with clinical data (<italic>n</italic>&#x2009;=&#x2009;36). The review of the literature allowed distinguishing two types of attenuated MPS VI phenotypes: osteoarticular and cardiac.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Literature review of patients with an attenuated phenotype of mucopolysaccharidosis type VI</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Case number (country)</th><th>Age at onset of symptoms/age at diagnosis (years)</th><th>Symptoms at onset</th><th>Clinical manifestations during disease course</th><th>Misdiagnosis/initial diagnosis</th><th>Genotype</th><th>Ref.</th></tr></thead><tbody><tr><td>1</td><td>nd</td><td>
<bold>HP</bold>
</td><td>CC, SK, VD</td><td>Perthes disease</td><td>nd</td><td>McKusick [<xref ref-type="bibr" rid="CR15">15</xref>]</td></tr><tr><td>2 (Germany)</td><td>7/40</td><td>
<bold>SK</bold>, TS (mild)</td><td>CC, CFF, CM, JS, SK, VD</td><td>Perthes disease</td><td>nd</td><td>Pilz et al. [<xref ref-type="bibr" rid="CR25">25</xref>]</td></tr><tr><td>3 (Germany)</td><td>10/38</td><td>
<bold>JD</bold>
</td><td>CC, CFF, CM, JS, SK, VD</td><td>nd</td><td>nd</td><td>Pilz et al. [<xref ref-type="bibr" rid="CR25">25</xref>]</td></tr><tr><td>4 (New Zealand)</td><td>nd/13</td><td>
<bold>FP</bold>
</td><td>CC, IH, SK, VD</td><td>nd</td><td>nd</td><td>Paterson et al. [<xref ref-type="bibr" rid="CR26">26</xref>]</td></tr><tr><td>5 (New Zealand)</td><td>nd/16</td><td>nd</td><td>CC, GR, IH, JS, SK, VD</td><td>nd</td><td>nd</td><td>Paterson et al. [<xref ref-type="bibr" rid="CR26">26</xref>]</td></tr><tr><td>6 (Denmark)</td><td>6/27</td><td>
<bold>HP</bold>, <bold>WG</bold>
</td><td>HD, RM</td><td>nd</td><td>nd</td><td>Tonnesen et al. [<xref ref-type="bibr" rid="CR27">27</xref>]</td></tr><tr><td>7 (New Zealand?)</td><td>4/9</td><td>GR, CC</td><td>CFF</td><td>nd</td><td>C192R/C192R</td><td>Isbrandt et al. [<xref ref-type="bibr" rid="CR9">9</xref>]</td></tr><tr><td>8 (nd)</td><td>nd/11</td><td>nd</td><td>CC, CFF, GR, IH, JS</td><td>nd</td><td>Y210C/-</td><td>Litjens et al. [<xref ref-type="bibr" rid="CR28">28</xref>]</td></tr><tr><td>9 (nd)</td><td>nd/13</td><td>nd</td><td>GR, IH, SK, VD</td><td>nd</td><td>R95Q/Y210C</td><td>Litjens et al. [<xref ref-type="bibr" rid="CR28">28</xref>]</td></tr><tr><td>10 (nd)</td><td>nd/16</td><td>nd</td><td>nd</td><td>nd</td><td>R95Q/Y210C</td><td>Litjens et al. [<xref ref-type="bibr" rid="CR28">28</xref>]</td></tr><tr><td>11 (nd)</td><td>nd/15</td><td>nd</td><td>CC, GR, H, JS, SK</td><td>nd</td><td>Y210C/-</td><td>Litjens et al. [<xref ref-type="bibr" rid="CR28">28</xref>]</td></tr><tr><td>12 (nd)</td><td>nd/17</td><td>nd</td><td/><td>nd</td><td>H393P/-</td><td>Litjens et al. [<xref ref-type="bibr" rid="CR28">28</xref>]</td></tr><tr><td>13 (nd)</td><td>nd/35</td><td>nd</td><td/><td>nd</td><td>T92M/L498P</td><td>Litjens et al. [<xref ref-type="bibr" rid="CR28">28</xref>]</td></tr><tr><td>14 (Denmark)</td><td>nd/44</td><td>nd</td><td>HA, PP, DL, H, IH, JS</td><td>nd</td><td>P313A/P481L</td><td>Brooks et al. [<xref ref-type="bibr" rid="CR29">29</xref>]</td></tr><tr><td>15 (Italy)</td><td>7/35</td><td>
<bold>SK</bold>, <bold>JP</bold>, <bold>JS</bold>
</td><td>CC, CFF, CTS, GR, JS, SK, VD</td><td>Carpal tunnel syndrome</td><td>Y210C/G302R</td><td>Scarpa et al. [<xref ref-type="bibr" rid="CR30">30</xref>]</td></tr><tr><td>16 (Italy)</td><td>nd/38</td><td>
<bold>HD</bold>, CH, RR</td><td>CC, CFF, JS, SK, VD</td><td>Suspected endocrine/rheumatologic disorder</td><td>Y210C/G302R</td><td>Scarpa et al. [<xref ref-type="bibr" rid="CR30">30</xref>]</td></tr><tr><td>17 (Ireland)</td><td>2/16</td><td>
<bold>BP</bold>, <bold>HP</bold>
</td><td>JP</td><td>nd</td><td>Y210C/Y210C</td><td>Gottwald et al. [<xref ref-type="bibr" rid="CR11">11</xref>]</td></tr><tr><td>18 (Germany)</td><td>11/29</td><td>
<bold>SK</bold>, CC, GR, RI</td><td>RA, VD, JP, SK, SCC, CC, GR, CM, IV</td><td>nd</td><td>R152W/Q104H</td><td>Th&#xFC;mler et al. [<xref ref-type="bibr" rid="CR31">31</xref>]</td></tr><tr><td>19 (Germany)</td><td>14/25</td><td>
<bold>SK</bold>, HC</td><td>CC, JC, VD, RA, RM, SK</td><td>nd</td><td>R152W/R152W</td><td/></tr><tr><td>20 (Germany)</td><td>10/25</td><td>RI, IH</td><td>JC, VD, JP, RM, SCC</td><td>nd</td><td>R160X/Y210C</td><td/></tr><tr><td>21 (Germany)</td><td>12/22</td><td>
<bold>HP</bold>, <bold>BP</bold>, <bold>SK</bold>
</td><td>VD, CTS, RM, SCC, SK</td><td>nd</td><td>R160X/Y210C</td><td/></tr><tr><td>22 (Turkey)</td><td>6/19</td><td>
<bold>HD</bold>/<bold>JP</bold>, <bold>RM</bold>, <bold>SK</bold>, CC</td><td>IV, VA, CCO, RA, CC, SCC, SK</td><td>nd</td><td>C192R/C192R</td><td/></tr><tr><td>23 (Germany)</td><td>11/24</td><td>
<bold>WG</bold>, <bold>HD</bold>, <bold>SK</bold>
</td><td>SK, JP, CC, CTS, VD, CCO, SK</td><td>nd</td><td>Y210C/W146X</td><td/></tr><tr><td>24 (Germany)</td><td>20/28</td><td>
<bold>HD</bold>, <bold>JC</bold>, <bold>CH</bold>, RI, RH</td><td>CFF, RM, CC, VD, SK, JS</td><td>nd</td><td>Y210C/?</td><td/></tr><tr><td>25 (Germany)</td><td>12/20</td><td>
<bold>HD</bold>, <bold>JC</bold>, <bold>CH</bold>, RI</td><td>CFF, CC, VD, SK, JS</td><td>nd</td><td>Y210C/?</td><td/></tr><tr><td>26 (Germany)</td><td>18/25</td><td>
<bold>HD</bold>, <bold>JC</bold>, <bold>CH</bold>, RI, VD</td><td>CFF, CC, VD, SK, JS</td><td>nd</td><td>Y210C/?</td><td/></tr><tr><td>27 (Poland)</td><td>21/37</td><td>
<bold>VD</bold>, JS (mild)</td><td>CC, CFF, GR, JS, SK</td><td>Rheumatic heart disease</td><td>R152W/R152W</td><td rowspan="2">Jurecka et al. [<xref ref-type="bibr" rid="CR8">8</xref>]</td></tr><tr><td>28 (Lithuania)</td><td>7/30</td><td>
<bold>VD</bold>, GR (mild)</td><td>CFF, GR, HC, IH, MC, JS, SCC, SK</td><td>Rheumatic heart disease</td><td>R152W/R152W</td></tr><tr><td>29 (Belarus)</td><td>15/22</td><td>
<bold>VD</bold>, GR (mild), CC (mild)</td><td>CC, CTS, GR, H, JS, SK</td><td>Chronic cardiac insufficiency</td><td>R152W/R152W</td><td rowspan="8"/></tr><tr><td>30 (Belarus)</td><td>15/22</td><td>
<bold>VD</bold>, JS (mild), GR (mild), CC (mild)</td><td>CC, CFF, CTS, GR, H, JS, SK</td><td>Chronic cardiac insufficiency</td><td>R152W/R152W</td></tr><tr><td>31 (Russia)</td><td>17/26</td><td>
<bold>VD</bold>, AGS (mild)</td><td>CFF, JS, GR, MC, SCC, SK</td><td>Chronic cardiac insufficiency</td><td>R152W/R152W</td></tr><tr><td>32 (Russia)</td><td>18/20</td><td>
<bold>VD</bold>, HI, JS (mild)</td><td>CFF, GR, MC, SK</td><td>Chronic cardiac insufficiency</td><td>R152W/R152W</td></tr><tr><td>33 (Lithuania)</td><td>15/23</td><td>
<bold>VD</bold>, GR (mild)</td><td>CFF, GR, IH, MC, JS, SK</td><td>Rheumatic heart disease</td><td>R152W/R152W</td></tr><tr><td>34 (Russia)</td><td>5/24</td><td>
<bold>VD</bold>, HI, CC (mild), GR</td><td>GR, CC, HS, JS, SK</td><td>Chronic cardiac insufficiency</td><td>R152W/R152W</td></tr><tr><td>35 (Lithuania)</td><td>6/15</td><td>
<bold>VD</bold>, AGS (mild), JS (mild)</td><td>CFF, GR, HC, JS, MC, SK</td><td>nd</td><td>R152W/R152W</td></tr><tr><td>36 (Belarus)</td><td>5/13</td><td>
<bold>VD</bold>, AGS (mild)</td><td>CTS, GR, JS, MC, RR, SK</td><td>nd</td><td>R152W/R152W</td></tr></tbody></table><table-wrap-foot><p>
<italic>nd</italic> no data, <italic>BP</italic> back pain, <italic>CC</italic> corneal clouding, <italic>CCO</italic> cardiac complications, <italic>CH</italic> claw hands, <italic>CFF</italic> coarse facial features, <italic>CM</italic> cervical myelopathy, <italic>CTS</italic> carpal tunnel syndrome, <italic>DL</italic> dyslexia, <italic>FP</italic> foot pain, <italic>AGS</italic> abnormal gait stereotype, <italic>GR</italic> growth retardation, <italic>H</italic> hepatomegaly, <italic>HA</italic> halitosis, <italic>HC</italic> hydrocephalus, <italic>HD</italic> hip dysplasia, <italic>HI</italic> inguinal hernia, <italic>HP</italic> hip pain, <italic>HS</italic> hepatosplenomegaly, <italic>IH</italic> impaired hearing, <italic>IV</italic> impaired vision, <italic>MC</italic> macrocephaly, <italic>JC</italic> joint contractures, <italic>JD</italic> joint dysfunction, <italic>JS</italic> joint stiffness, <italic>JP</italic> joint pain, <italic>PP</italic> photophobia, <italic>RA</italic> respiratory abnormalities, <italic>RH</italic> recurrent hernia, <italic>RI</italic> recurrent infections, <italic>RM</italic> reduced mobility, <italic>RR</italic> recurrent rhinitis, <italic>SCC</italic> spinal cord compression, <italic>SK</italic> skeletal abnormalities, <italic>TS</italic> tetraspasticity, <italic>VD</italic> valve disease, <italic>WG</italic> waddling gait</p></table-wrap-foot></table-wrap></p>
          <p>In a majority of reported patients, a relatively attenuated phenotype meant an essentially osteoarticular phenotype. These patients initially presented with bone and joint symptoms, especially pain and stiffness in the joints, joint contractures, and hip and back pain. At some point, most of these patients developed serious manifestations of the disease including joint degeneration, sleep apnea, a decrease in pulmonary function, reduced endurance, cardiac valve disease, and skeletal complications including carpal tunnel syndrome and hip disease.</p>
          <p>Unlike the majority of reviewed patients, patients homozygous for p.R152W mutation showed a significantly different clinical phenotype with predominance of cardiovascular manifestations [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p>
        </sec>
        <sec id="Sec11">
          <title>Genotype&#x2013;phenotype correlation</title>
          <p>Mutations associated with an attenuated MPS VI phenotype are presented in Table&#xA0;<xref rid="Tab3" ref-type="table">3</xref>.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Characteristics of the changes in the <italic>ARSB</italic> gene associated with an attenuated MPS VI phenotype</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Location</th><th>Change at DNA level<sup>a</sup>
</th><th>Predicted effect on amino acid sequence of the protein</th><th>Type of mutation</th><th>Reference</th></tr></thead><tbody><tr><td>Ex. 1</td><td>c.247G&gt;C</td><td>p.D83Y</td><td>Missense</td><td>Karageorgos et al. [<xref ref-type="bibr" rid="CR10">10</xref>]</td></tr><tr><td>Ex. 2</td><td>c.454C&gt;T</td><td>p.R152W</td><td>Missense</td><td>Voskoboeva et al. [<xref ref-type="bibr" rid="CR32">32</xref>]</td></tr><tr><td rowspan="2">Ex. 3</td><td>c.574T&gt;C</td><td>p.C192R</td><td>Missense</td><td>Isbrandt et al. [<xref ref-type="bibr" rid="CR9">9</xref>]</td></tr><tr><td>c.629A&gt;G</td><td>p.Y210C</td><td>Missense</td><td>Litjens et al. [<xref ref-type="bibr" rid="CR4">4</xref>]</td></tr><tr><td rowspan="2">Ex. 7</td><td>c.1214G&gt;A</td><td>p.C405Y</td><td>Missense</td><td>Karageorgos et al. [<xref ref-type="bibr" rid="CR10">10</xref>]</td></tr><tr><td>c.1301G&gt;T</td><td>p.R434I</td><td>Missense</td><td>Karageorgos et al. [<xref ref-type="bibr" rid="CR10">10</xref>]</td></tr></tbody></table><table-wrap-foot><p>
<italic>Ex</italic> exon</p><p>
<sup>a</sup>NCBI reference sequence: NM_000046.3 (cDNA considering A of the ATG translation initiation codon as nucleotide +1)</p></table-wrap-foot></table-wrap></p>
          <p>Apart from the p.R152W and p.Y210C mutations, other mutations have been reported as associated with attenuated disease progression: p.C192R [<xref ref-type="bibr" rid="CR9">9</xref>] when present in homozygous state and p.D83Y [<xref ref-type="bibr" rid="CR10">10</xref>], p.C405Y [<xref ref-type="bibr" rid="CR10">10</xref>], and p.R434I [<xref ref-type="bibr" rid="CR10">10</xref>] when present in compound heterozygous states. Osteoarticular attenuated phenotype is predominantly associated with a missense mutation p.Y210C, while cardiac with p.R152W in homozygosity. So far, only one patient homozygous for p.Y210C mutation has been described in the literature, while in the majority of patients, this mutation is present with other mis- or nonsense mutation [<xref ref-type="bibr" rid="CR11">11</xref>].</p>
        </sec>
      </sec>
    </sec>
    <sec id="Sec12" sec-type="discussion">
      <title>Discussion</title>
      <p>One of the first descriptions of mucopolysaccharidosis type VI was probably by the neurologist Nonne [<xref ref-type="bibr" rid="CR12">12</xref>]. After several investigators indicated heterogeneity of MPS VI based on radiological findings, the patients&#x2019; size, and longevity [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>], McKusick suggested separating a severe form (mucopolysaccharidosis type VIA) from a mild variant (type VIB) [<xref ref-type="bibr" rid="CR15">15</xref>]. Based on McKusick&#x2019;s classification, the longevity, size, lack of cardiac insufficiency in association with mild cardiac murmurs, lack of abnormality of sella turcica, and the absence of umbilical or inguinal hernia, marked hepatosplenomegaly, and marked corneal opacities warranted the diagnosis of the mild B variant of MPS VI [<xref ref-type="bibr" rid="CR15">15</xref>]. Apart from severe and attenuated phenotypes, descriptive classification systems have also described an intermediate disease form. Other authors suggested other classification systems based on height and urinary glycosaminoglycan (uGAG) levels, the age at the onset of symptoms, patient&#x2019;s height, and the age of death [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. In reality, there are no fixed parameters to ascribe a particular patient to a single category, and the decision is subjective depending on physician&#x2019;s experience and knowledge. The relatively attenuated disease form is generally characterized by later onset of symptoms which may not at first appear in a recognized pattern, but when apparent, the milder symptoms may be observed by an alert physician and lead ultimately to diagnosis usually after 5&#xA0;years of age, but it may be delayed until the second or third decades.</p>
      <p>Results from our study and review of the literature allow for distinguishing two types of attenuated MPS VI phenotypes: osteoarticular and cardiac. It is likely that patients with osteoarticular symptoms will be found in either rheumatology or orthopedic clinics. The similarity of attenuated MPS VI to the more commonly seen rheumatological conditions means that patients are often misdiagnosed and there is a delay before the patient&#x2019;s symptoms are attributed to MPS. Patients with a cardiac variant of MPS VI are much more probable to be found in cardiology clinics [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. In these patients, cardiac disease progresses silently and ultimately leading to heart failure and does not correspond with the other typical MPS features which are very mild or absent [<xref ref-type="bibr" rid="CR8">8</xref>]. An advanced valve defect is an indication for valve surgery, which may be beneficial in these patients at an earlier stage of the disease. In both phenotypes, the pathological process seems to be restricted at first to one system only, either osteoarticular or cardiovascular. In the cardiac phenotype, however, it tends to have more serious complications leading to fast disease progression and abrupt death [<xref ref-type="bibr" rid="CR7">7</xref>].</p>
      <p>Despite the utility of communicating with these descriptive categories, it is important to recognize that the symptoms of the disease manifested along a continuum. Using a descriptive classification is very helpful for clinicians; however, it is important to bear in mind its implications. The term attenuated (or used by some slowly progressing) implies a slower disease progression, and it may be perceived that these patients do not require treatment as urgently as severe patients. The truth is that these patients may remain asymptomatic for years with silently (but not necessarily slowly) progressing disease and be recognized in an advanced disease stage when it is too late for any intervention [<xref ref-type="bibr" rid="CR7">7</xref>]. For this reason, we previously suggested using a term <italic>cardiac MPS VI variant</italic> to add a sense of urgency as these patients require treatment to be administered prior to the onset of valve disease [<xref ref-type="bibr" rid="CR8">8</xref>].</p>
      <p>The awareness among cardiologists and rheumatologists should be raised so they can play an important role, not only in the management but also in the diagnosis of these patients [<xref ref-type="bibr" rid="CR18">18</xref>]. The extent of cardiac involvement may be underestimated in patients with mucopolysaccharidosis because of restrictive pulmonary disease and skeletal abnormalities that limit patients&#x2019; activities [<xref ref-type="bibr" rid="CR19">19</xref>]. We have previously presented a diagnostic algorithm, suggesting uGAG analysis in any patient with valve disease even in the presence of very mild or untypical disease symptoms [<xref ref-type="bibr" rid="CR18">18</xref>]. In cases with a high index of suspicion such as those with a positive family history or those with other characteristic features of MPS VI, enzymatic activity should be determined even if uGAG excretion is low. As attenuated patients may still be very difficult to recognize, the delay in diagnosis may make it difficult to influence valve disease with available treatment. Apart from this, we have to bear in mind that the usefulness of enzyme replacement therapy is limited due to the fact that a given enzyme preparation does not have beneficial effects on all aspects of a disorder in the same degree. The effect of ERT alone on cardiac structure and function in MPS patients has been documented in only a few studies [<xref ref-type="bibr" rid="CR20">20</xref>&#x2013;<xref ref-type="bibr" rid="CR23">23</xref>] and larger studies with longer follow-up are still needed. Additionally, clinical studies have shown that many symptoms of mucopolysaccharidoses even after long-term treatment are not anymore reversible. It seems probable that in the future, a tailored combination therapy using ERT with novel therapeutic options such as application of small molecules that either inhibit a key enzyme which is responsible for substrate synthesis (substrate deprivation) or act as a chaperone to increase the residual activity of the lysosomal enzyme (enzyme-enhancing therapy) will be the most effective [<xref ref-type="bibr" rid="CR24">24</xref>].</p>
      <p>By identifying patient&#x2019;s genotype, it may be possible to predict the course of the disease and establish more tailored treatment plan. Patients with the p.Y210C mutation should be covered by a special care team of orthopedists, physiotherapists, and rheumatologists with a plan of rehabilitation, proper early use of orthoses and other support devices, the best determination of time for bone and joint surgery, and application of drug treatments. Patients with the p.R152W should be referred to a cardiologist before the appearance of symptoms from the circulatory system. The mechanism why the p.R152W mutation seems to have a special affinity for the heart valves remains unknown. Perhaps this stems from the specific structure of the valves, and each of these mutations causes different residual enzyme activity. Detecting these differences would explain the process of affecting different organs dependent on the flow dynamics of the substrate.</p>
    </sec>
    <sec id="Sec13" sec-type="conclusion">
      <title>Conclusions</title>
      <p>
        <list list-type="order">
          <list-item>
            <p>Based on the literature review, two types of attenuated MPS VI phenotypes can be distinguished: osteoarticular and cardiac, both with a clear genotype&#x2013;phenotype correlation.</p>
          </list-item>
          <list-item>
            <p>The majority of MPS VI patients reported so far as relatively attenuated presented with an essentially osteoarticular phenotype associated with p.Y210C mutation in heterozygosity.</p>
          </list-item>
          <list-item>
            <p>The term attenuated should be used with caution as it may imply the slow disease progression and the lack of urgency to treat these patients.</p>
          </list-item>
        </list>
      </p>
    </sec>
  </body>
  <back>
    <ack>
      <p>The authors thank the Polish MPS Society (&#x201C;Stowarzyszenie Chorych na Mukopolisacharydoz&#x119; i Choroby Rzadkie&#x201D;) and, in particular, its president, Teresa Matulka, for inviting Lithuanian and Belarusian patients to the society&#x2019;s annual meeting, which allowed us to collect the data and examine the patients. We would also like to express our gratitude to Prof. W&#x119;grzyn and Dr. Ewa Piotrowska (University of Gda&#x144;sk, Poland) as well as Dr. Opoka-Winiarska (Medical University of Lublin, Poland) for their critical reading of the manuscript. The authors would like to thank Prof. Nina Gusina (Institute for Hereditary Diseases, Minsk, Belarus) for providing clinical information about her patient.</p>
      <sec id="d30e1982">
        <title>Disclosures </title>
        <p>None.</p>
      </sec>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Neufeld</surname>
              <given-names>EF</given-names>
            </name>
            <name>
              <surname>Muenzer</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Scriver</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Beaudet</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Sly</surname>
              <given-names>WS</given-names>
            </name>
          </person-group>
          <article-title>The mucopolysaccharidoses</article-title>
          <source>The metabolic and molecular basis of inherited disease</source>
          <year>2001</year>
          <publisher-loc>New York</publisher-loc>
          <publisher-name>McGraw-Hill</publisher-name>
          <fpage>3421</fpage>
          <lpage>3452</lpage>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Opoka-Winiarska</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Jurecka</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Emeryk</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tylki-Szymanska</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Osteoimmunology in mucopolysaccharidoses type I, II, VI and VII. Immunological regulation of the osteoarticular system in the course of metabolic inflammation</article-title>
          <source>Osteoarthr Cartilage</source>
          <year>2013</year>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Valayannopoulos</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Nicely</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Harmatz</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Turbeville</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Mucopolysaccharidosis VI</article-title>
          <source>Orphanet J Rare Dis</source>
          <year>2010</year>
          <volume>5</volume>
          <issue>1</issue>
          <fpage>5</fpage>
          <pub-id pub-id-type="pmid">20385007</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Malm</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lund</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Mansson</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Heiberg</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Mucopolysaccharidoses in the Scandinavian countries: incidence and prevalence</article-title>
          <source>Acta Paediatr</source>
          <year>2008</year>
          <volume>97</volume>
          <issue>11</issue>
          <fpage>1577</fpage>
          <lpage>1581</lpage>
          <pub-id pub-id-type="pmid">18681890</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baehner</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Schmiedeskamp</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Krummenauer</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Miebach</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bajbouj</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Whybra</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kohlschutter</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kampmann</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Beck</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Cumulative incidence rates of the mucopolysaccharidoses in Germany</article-title>
          <source>J Inherit Metab Dis</source>
          <year>2005</year>
          <volume>28</volume>
          <issue>6</issue>
          <fpage>1011</fpage>
          <lpage>1017</lpage>
          <pub-id pub-id-type="pmid">16435194</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jurecka</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Piotrowska</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Cimbalistiene</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gusina</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Sobczynska</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Czartoryska</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Czerska</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ounap</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Wegrzyn</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Tylki-Szymanska</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Molecular analysis of mucopolysaccharidosis type VI in Poland, Belarus, Lithuania and Estonia</article-title>
          <source>Mol Genet Metab</source>
          <year>2012</year>
          <volume>105</volume>
          <issue>2</issue>
          <fpage>237</fpage>
          <lpage>243</lpage>
          <pub-id pub-id-type="pmid">22133300</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jurecka</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Golda</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Opoka-Winiarska</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Piotrowska</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Tylki-Szymanska</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Mucopolysaccharidosis type VI (Maroteaux&#x2013;Lamy syndrome) with a predominantly cardiac phenotype</article-title>
          <source>Mol Genet Metab</source>
          <year>2011</year>
          <volume>104</volume>
          <issue>4</issue>
          <fpage>695</fpage>
          <lpage>699</lpage>
          <pub-id pub-id-type="pmid">21917494</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jurecka</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zakharova</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Cimbalistiene</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gusina</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kulpanovich</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Golda</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Opoka-Winiarska</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Piotrowska</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Voskoboeva</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Tylki-Szyma&#x144;ska</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Mucopolysaccharidosis type VI: a predominantly cardiac phenotype associated with a homozygosity for p.R152W mutation in the <italic>ARSB</italic> gene</article-title>
          <source>Am J Med Genet</source>
          <year>2013</year>
          <volume>161</volume>
          <issue>6</issue>
          <fpage>1291</fpage>
          <lpage>1299</lpage>
          <pub-id pub-id-type="pmid">23633437</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Isbrandt</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Arlt</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Brooks</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Hopwood</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>von Figura</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Peters</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Mucopolysaccharidosis VI (Maroteaux&#x2013;Lamy syndrome): six unique arylsulfatase B gene alleles causing variable disease phenotypes</article-title>
          <source>Am J Hum Genet</source>
          <year>1994</year>
          <volume>54</volume>
          <issue>3</issue>
          <fpage>454</fpage>
          <lpage>463</lpage>
          <pub-id pub-id-type="pmid">8116615</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Karageorgos</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Brooks</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Pollard</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Melville</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Hein</surname>
              <given-names>LK</given-names>
            </name>
            <name>
              <surname>Clements</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Ketteridge</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Swiedler</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Beck</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Giugliani</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Harmatz</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Wraith</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Guffon</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Le&#xE3;o Teles</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>S&#xE1; Miranda</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Hopwood</surname>
              <given-names>JJ</given-names>
            </name>
          </person-group>
          <article-title>Mutational analysis of 105 mucopolysaccharidosis type VI patients</article-title>
          <source>Hum Mutat</source>
          <year>2007</year>
          <volume>28</volume>
          <issue>9</issue>
          <fpage>897</fpage>
          <lpage>903</lpage>
          <pub-id pub-id-type="pmid">17458871</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gottwald</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Stewart</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Tylee</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Church</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>SA</given-names>
            </name>
          </person-group>
          <article-title>Attenuated mucopolysaccharidosis type VI (Maroteaux&#x2013;Lamy syndrome) due to homozygosity for the p.Y210C mutation in the ARSB gene</article-title>
          <source>Mol Genet Metab</source>
          <year>2011</year>
          <volume>103</volume>
          <issue>3</issue>
          <fpage>300</fpage>
          <lpage>302</lpage>
          <pub-id pub-id-type="pmid">21514195</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nonne</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Familiares Vorkommen (3 Geschwister) einer Kombination von imperfekter Chondrodystrophie mit imperfektem Myxoedema infantilis</article-title>
          <source>Dtsch Z Nervenheilkd</source>
          <year>1925</year>
          <volume>83</volume>
          <fpage>263</fpage>
          <lpage>273</lpage>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rampini</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Maroteaux</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>An uncommon phenotype of Hurler&#x2019;s syndrome</article-title>
          <source>Helv Paediatr Acta</source>
          <year>1966</year>
          <volume>21</volume>
          <issue>4</issue>
          <fpage>376</fpage>
          <lpage>386</lpage>
          <pub-id pub-id-type="pmid">4968595</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Spranger</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Koch</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>McKusick</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Natzschka</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wiedemann</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Zellweger</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Mucopolysaccharidosis VI (Maroteaux&#x2013;Lamy&#x2019;s disease)</article-title>
          <source>Helv Paediatr Acta</source>
          <year>1970</year>
          <volume>25</volume>
          <issue>4</issue>
          <fpage>337</fpage>
          <lpage>362</lpage>
          <pub-id pub-id-type="pmid">4250491</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>McKusick</surname>
              <given-names>VA</given-names>
            </name>
          </person-group>
          <source>Heritable disorders of connective tissue</source>
          <year>1972</year>
          <edition>4</edition>
          <publisher-loc>St. Louis</publisher-loc>
          <publisher-name>Mosby</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Swiedler</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Beck</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bajbouj</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Giugliani</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Harmatz</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Wraith</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ketteridge</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hopwood</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Guffon</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Sa Miranda</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Teles</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Berger</surname>
              <given-names>KI</given-names>
            </name>
            <name>
              <surname>Piscia-Nichols</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with mucopolysaccharidosis VI (Maroteaux&#x2013;Lamy syndrome)</article-title>
          <source>Am J Med Genet A</source>
          <year>2005</year>
          <volume>134A</volume>
          <issue>2</issue>
          <fpage>144</fpage>
          <lpage>150</lpage>
          <pub-id pub-id-type="pmid">15690405</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Petry</surname>
              <given-names>MFG</given-names>
            </name>
            <name>
              <surname>Nonemacher</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sebben</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>IVD</given-names>
            </name>
            <name>
              <surname>Azevedo</surname>
              <given-names>ACM</given-names>
            </name>
            <name>
              <surname>Burin</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Rezende</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Giugliani</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Leistner-Segal</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Mucopolysaccharidosis type VI: identification of novel mutations on the arylsulphatase B gene in South American patients</article-title>
          <source>J Inherit Metab Dis</source>
          <year>2005</year>
          <volume>28</volume>
          <issue>6</issue>
          <fpage>1027</fpage>
          <lpage>1034</lpage>
          <pub-id pub-id-type="pmid">16435196</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Golda</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Jurecka</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Opoka-Winiarska</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Tylki-Szymanska</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Mucopolysaccharidosis type VI: a cardiologist&#x2019;s guide to diagnosis and treatment</article-title>
          <source>Int J Cardiol</source>
          <year>2013</year>
          <volume>167</volume>
          <issue>1</issue>
          <fpage>1</fpage>
          <lpage>10</lpage>
          <pub-id pub-id-type="pmid">22704873</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Golda</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Jurecka</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tylki-Szymanska</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Cardiovascular manifestations of mucopolysaccharidosis type VI (Maroteaux&#x2013;Lamy syndrome)</article-title>
          <source>Int J Cardiol</source>
          <year>2011</year>
          <volume>158</volume>
          <issue>1</issue>
          <fpage>6</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="pmid">21737154</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fesslova</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Corti</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sersale</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Rovelli</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Russo</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Mannarino</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Butera</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Parini</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>The natural course and the impact of therapies of cardiac involvement in the mucopolysaccharidoses</article-title>
          <source>Cardiol Young</source>
          <year>2009</year>
          <volume>19</volume>
          <issue>2</issue>
          <fpage>170</fpage>
          <lpage>178</lpage>
          <pub-id pub-id-type="pmid">19195419</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Braunlin</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Berry</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Whitley</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I</article-title>
          <source>Am J Cardiol</source>
          <year>2006</year>
          <volume>98</volume>
          <issue>3</issue>
          <fpage>416</fpage>
          <lpage>418</lpage>
          <pub-id pub-id-type="pmid">16860035</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wraith</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Beck</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lane</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>van der Ploeg</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Shapiro</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Xue</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kakkis</surname>
              <given-names>ED</given-names>
            </name>
            <name>
              <surname>Guffon</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-<sc>l</sc>-iduronidase (laronidase)</article-title>
          <source>Pediatrics</source>
          <year>2007</year>
          <volume>120</volume>
          <issue>1</issue>
          <fpage>e37</fpage>
          <lpage>e46</lpage>
          <pub-id pub-id-type="pmid">17606547</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Okuyama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ida</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Cox</surname>
              <given-names>GF</given-names>
            </name>
            <name>
              <surname>Eto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Orii</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (mucopolysaccharidosis II, MPS II)</article-title>
          <source>Mol Genet Metab</source>
          <year>2010</year>
          <volume>99</volume>
          <issue>1</issue>
          <fpage>18</fpage>
          <lpage>25</lpage>
          <pub-id pub-id-type="pmid">19773189</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beck</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy</article-title>
          <source>Hum Genet</source>
          <year>2007</year>
          <volume>121</volume>
          <issue>1</issue>
          <fpage>1</fpage>
          <lpage>22</lpage>
          <pub-id pub-id-type="pmid">17089160</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <mixed-citation publication-type="other">Pilz H, von Figura K, Goebel HH (1979) Deficiency of arylsulfatase B in 2 brothers aged 40 and 38 years (Maroteaux-Lamy syndrome, type B). Ann Neurol 6(4):315&#x2013;325. doi:10.1002/ana.410060405</mixed-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <mixed-citation publication-type="other">Paterson DE, Harper G, Weston HJ, Mattingley J (1982) Maroteaux-Lamy syndrome, mild form--MPS vi b. Br J Radiol 55(659):805&#x2013;812</mixed-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <mixed-citation publication-type="other">Tonnesen T, Gregersen HN, Guttler F (1991) Normal MPS excretion, but dermatan sulphaturia, combined with a mild Maroteaux-Lamy phenotype. J Med Genet 28(7):499&#x2013;501</mixed-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <mixed-citation publication-type="other">Litjens T, Brooks DA, Peters C, Gibson GJ, Hopwood JJ (1996) Identification, expression, and biochemical characterization of N-acetylgalactosamine-4-sulfatase mutations and relationship with clinical phenotype in MPS-VI patients. Am J Hum Genet 58(6):1127&#x2013;1134</mixed-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <mixed-citation publication-type="other">Brooks DA, Gibson GJ, Karageorgos L, Hein LK, Robertson EF, Hopwood JJ (2005) An index case for the attenuated end of the mucopolysaccharidosis type VI clinical spectrum. Mol Genet Metab 85(3):236&#x2013;238. doi:10.1016/j.ymgme.2005.02.008</mixed-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <mixed-citation publication-type="other">Scarpa M, Buffone E, La Marca P, Campello M, Rampazzo A (2010) Difficulties in diagnosing slowly progressive mucopolysaccharidosis VI: a case series. Journal of pediatric rehabilitation medicine 3:71&#x2013;75</mixed-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <mixed-citation publication-type="other">Th&#xFC;mler A, Miebach E, Lampe C, Pitz S, Kamin W, Kampmann C, Link B, Mengel E (2012) Clinical characteristics of adults with slowly progressing mucopolysaccharidosis VI: a case series. J Inherit Metab Dis 35(6):1071&#x2013;1079. doi:10.1007/s10545-012-9474-1</mixed-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <mixed-citation publication-type="other">Voskoboeva E, Isbrandt D, von Figura K, Krasnopolskaya X, Peters C (1994) Four novel mutant alleles of the arylsulfatase B gene in two patients with intermediate form of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Hum Genet 93(3):259-264</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
